Top Massachusetts Biotech Startups (258)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in...
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a...
We believe it is time to bring a fresh approach to treating common illnesses. We are Vesalius Therapeutics.
Scismic is a tech platform built by scientists to help biotechs grow qualified and diverse scientific teams. Our specialized algorithm accurately targets relevant candidates for faster hiring. We are funded by the NIH to reduce bias in candidate evaluation through our gender- and race-blind skills matching technology, so you can hire scientists from all walks of life with the skills...
X4 Pharmaceuticals develops and commercializes therapies for rare diseases of the immune system, with a focus on rare hematology conditions and significant unmet needs. Its expertise includes immune-system and CXCR4 biology. The company developed mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI for WHIM syndrome, and is advancing it in a global Phase 3 trial...
Curiox Biosystems is committed to enabling accurate biological analysis through automation. Next-generation methods and applications--including single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy--deserve a next-generation approach to preparing samples for analysis. That’s why Curiox invented Laminar Wash technology, the only sample preparation method that eliminates centrifugation and the problems it introduces. The methodology keeps cells in their...
Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.
Solid Biosciences is a precision genetic medicine company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and genetic cardiomyopathies. The company also develops genetic regulators and other enabling technologies intended to improve gene-therapy delivery. Founded by people directly affected by Duchenne, its mission is...
Machine Learning for Drug Discovery. PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster. We've raised $26M from top investors, secured a $68M NIH partnership to prevent pandemics, and established a $260M partnership with Pfizer. We also launched and help lead the world's largest open-science initiative to find a COVID antiviral;...
Seismic Therapeutic is a clinical-stage biotechnology company developing biologic medicines for autoimmune and inflammatory diseases. Its IMPACT platform integrates machine learning with structural biology, protein engineering and translational immunology to discover and optimize novel therapies targeting dysregulated adaptive immunity. The company seeks to accelerate biologics development and create medicines with improved therapeutic properties for patients with immune-driven conditions.
Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and...
Pulmovant is a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases and is a Roivant (Nasdaq: ROIV) company. Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD). Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a...
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique...
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to...
Pillar Biosciences was founded in 2014, on the principle that in order for personalized medicine to be realized, clinical Next Generation Sequencing (NGS) workflows need to be affordable, rapid, robust, and flexible. We’re focused on productive solutions that enable streamlined workflows, so that labs can generate dependable results with less inputs, less labor, and less time. Our team makes precision...
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies to improve outcomes for people living with cancer while avoiding the systemic side effects of current treatments. Using its proprietary platform, it advances a pipeline of novel clinical- and preclinical-stage molecules designed to optimize therapeutic index by localizing anti-tumor activity within the tumor microenvironment. These therapies are...


































